BRPI0918842A2 - método para tratar pacientes com esclerose múltipla com anticorpos anti-il2r - Google Patents

método para tratar pacientes com esclerose múltipla com anticorpos anti-il2r

Info

Publication number
BRPI0918842A2
BRPI0918842A2 BRPI0918842A BRPI0918842A BRPI0918842A2 BR PI0918842 A2 BRPI0918842 A2 BR PI0918842A2 BR PI0918842 A BRPI0918842 A BR PI0918842A BR PI0918842 A BRPI0918842 A BR PI0918842A BR PI0918842 A2 BRPI0918842 A2 BR PI0918842A2
Authority
BR
Brazil
Prior art keywords
multiple sclerosis
treating multiple
sclerosis patients
il2r antibodies
il2r
Prior art date
Application number
BRPI0918842A
Other languages
English (en)
Inventor
Randy R Robinson
Original Assignee
Abbott Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotherapeutics Corp filed Critical Abbott Biotherapeutics Corp
Publication of BRPI0918842A2 publication Critical patent/BRPI0918842A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0918842A 2008-08-28 2009-08-28 método para tratar pacientes com esclerose múltipla com anticorpos anti-il2r BRPI0918842A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19036208P 2008-08-28 2008-08-28
PCT/US2009/055294 WO2010025321A2 (en) 2008-08-28 2009-08-28 Method for treating multiple sclerosis patients with anti-il2r antibodies

Publications (1)

Publication Number Publication Date
BRPI0918842A2 true BRPI0918842A2 (pt) 2015-12-08

Family

ID=41581181

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918842A BRPI0918842A2 (pt) 2008-08-28 2009-08-28 método para tratar pacientes com esclerose múltipla com anticorpos anti-il2r

Country Status (7)

Country Link
US (1) US20100055098A1 (pt)
EP (1) EP2318437A2 (pt)
AU (1) AU2009285625A1 (pt)
BR (1) BRPI0918842A2 (pt)
CA (1) CA2730909A1 (pt)
RU (1) RU2011111391A (pt)
WO (1) WO2010025321A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126890A1 (en) * 2009-04-27 2010-11-04 Facet Biotech Corporation Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
CA2771335A1 (en) * 2009-08-31 2011-03-03 Abbott Biotherapeutics Corp. Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
EP2470901A1 (en) * 2009-10-30 2012-07-04 Abbott Biotherapeutics Corp. Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
JP6055615B2 (ja) 2011-05-27 2016-12-27 アッヴィ バイオテクノロジー リミテッド Ｄａｃｈｙｐ組成物および方法
CA2844662A1 (en) * 2011-08-08 2013-02-14 Abbvie Biotherapeutics Inc. Methods of treating progressive forms of multiple sclerosis
AU2016341529B2 (en) 2015-10-22 2023-03-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
RU2721282C2 (ru) * 2017-11-21 2020-05-18 Илья Владимирович Духовлинов Способ лечения рассеянного склероза (варианты)
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN114805586A (zh) * 2022-04-14 2022-07-29 天津华科泰生物技术有限公司 抗MxA单克隆抗体组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
WO2004089973A2 (en) * 1997-01-23 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
AU2002368055B2 (en) * 2002-06-28 2008-09-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
WO2006042101A1 (en) * 2004-10-06 2006-04-20 The Government Of The United States As Represented By The Secretary Of Health And Human Services Method for treating active uveitis

Also Published As

Publication number Publication date
EP2318437A2 (en) 2011-05-11
AU2009285625A1 (en) 2010-03-04
CA2730909A1 (en) 2010-03-04
RU2011111391A (ru) 2012-10-10
WO2010025321A2 (en) 2010-03-04
WO2010025321A3 (en) 2010-05-20
US20100055098A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
BRPI0918842A2 (pt) método para tratar pacientes com esclerose múltipla com anticorpos anti-il2r
IL287311A (en) Antibodies and processes for preparing the same
PT2427212T (pt) Anticorpos anti-cd100 e métodos para utilização dos mesmos
IL232222A0 (en) Methods for treating progressive multiple sclerosis
BRPI0917145A2 (pt) Método para fabricar biocombustíveis
BRPI0910608A2 (pt) métodos e sistemas para avaliar resultados clínicos
PT2853545T (pt) Anticorpo específico para ige
BRPI0917204A2 (pt) variantes estruturais de anticorpos para melhores características terapêuticas
SI3156422T1 (sl) Človeška protitelesa z visoko afiniteto do PCSK9
BR112013007678A2 (pt) método para tratamento de doenças alérgicas
BRPI0822447A2 (pt) Anticorpo monoclonal e método do mesmo
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI0912173A2 (pt) anticorpos anti-flt3
BRPI0918178A2 (pt) anticorpos monoclonais para tratamento de câncer
BRPI0910587A2 (pt) método e aparelho para eletrogalvanização
BRPI0812446A2 (pt) Métodos para aperfeiçoamento de propriedades de proteína múltiplas
BR112013030381A2 (pt) reagentes e métodos para tratar doença dental
BRPI1014262A2 (pt) anticorpos específicos para caderina-17
CR10705A (es) Anticuerpos para linfotoxina-alfa
BRPI0913074A2 (pt) pneumático e método para sua fabricação
BRPI0918419A2 (pt) nova formulação anticorpo
BRPI0916787A2 (pt) artigo, e, método para fabricar um artigo
EP2207803A4 (en) Cd9-specific human antibodies
PT2646466T (pt) Meios e métodos para produzir anticorpos de alta afinidade
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]